By Colin Kellaher


Shares of HilleVax Inc. moved higher in their trading debut Friday after the vaccine developer's upsized initial public offering was priced at the midpoint of expectations.

HilleVax shares were recently changing hands at $18.61, up about 9.5%, after opening at $18.76.

The Boston clinical-stage biopharmaceutical company sold nearly 11.8 million shares at $17 each in the IPO, compared with prior plans to offer about 10.3 million shares at between $16 and $18 apiece.

Takeda Pharmaceutical Co. and private-equity firm Frazier Healthcare Partners last year formed HilleVax to develop and commercialize Takeda's norovirus vaccine candidate.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

04-29-22 1208ET